Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis

European Journal of Cancer Prevention

Volumn 25, Issue 3, 2016, Pages 206-215

  Shirakami, Yohei ^a   Shimizu, Masahito ^a   Kubota, Masaya ^a   Ohno, Tomohiko ^a   Kochi, Takahiro ^a   Nakamura, Nobuhiko ^a   Sumi, Takafumi ^a   Tanaka, Takuji ^b   Moriwaki, Hisataka ^a   Seishima, Mitsuru ^a  

^a GIFU UNIVERSITY   (Japan)

^b Department of Cancer Research and Prevention   (Japan)

Author keywords

Fatty liver; Lipogenesis; Liver tumorigenesis; Nonalcoholic steatohepatitis; Obesity; Pentoxifylline

Indexed keywords

ACYL COENZYME A DESATURASE 1; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; FATTY ACID; FATTY ACID SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL OBESITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; HEPATITIS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY MASS; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER INJURY; LIVER WEIGHT; LOW DRUG DOSE; MACROPHAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STELLATE CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ANIMAL; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; INFLAMMATION; LIVER NEOPLASMS, EXPERIMENTAL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PRECANCEROUS CONDITIONS;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; INFLAMMATION; LIPOGENESIS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PENTOXIFYLLINE; PRECANCEROUS CONDITIONS; VASODILATOR AGENTS;

EID: 84962053014     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000172     Document Type: Article

References (48)

1. Ai ZL, Zhu CH, Min M, Wang J, Lan CH, Fan LL, et al. (2011). The role of hepatic liver X receptor alpha- and sterol regulatory element binding protein-1cmediated lipid disorder in the pathogenesis of non-alcoholic steatohepatitis in rats. J Int Med Res 39:1219-1229.
2. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S (1997). Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40:470-474.
3. Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, et al. (2012). Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 5:544-552.
4. Blaslov K, Bulum T, Zibar K, Duvnjak L (2014). Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 20:7356-7365.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348:1625-1638.
6. Chae MK, Park SG, Song SO, Kang ES, Cha BS, Lee HC, et al. (2012). Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF-alpha expression and endoplasmic reticulum stress. Exp Diabetes Res 2012:762565.
7. Chen X, Xun K, Chen L, Wang Y (2009). TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct 27:407-416.
8. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008). Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18:54-61.
9. El-Lakkany N, el-Din SS, Ebeid F (2011). The use of pentoxifylline as adjuvant therapy with praziquantel downregulates profibrogenic cytokines, collagen deposition and oxidative stress in experimental schistosomiasis mansoni. Exp Parasitol 129:152-157.
10. El-Serag HB, Tran T, Everhart JE (2004). Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-468.
11. Faienza MF, Francavilla R, Goffredo R, Ventura A, Marzano F, Panzarino G, et al. (2012). Oxidative stress in obesity and metabolic syndrome in children and adolescents. Horm Res Paediatr 78:158-164.
12. Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, et al. (2010). Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 51:3046-3054.
13. Folch J, Lees M, Sloane Stanley GH (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
14. Frith CH, Ward JM, Turusov VS (1994). Tumours of the liver. IARC Sci Publ 223-269.
15. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, et al. (2010). Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol Res 40:376-382.
16. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, et al. (2010). Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 101:460-467.
17. Iwasa M, Kobayashi Y, Mifuji-Moroka R, Hara N, Miyachi H, Sugimoto R, et al. (2013). Branched-chain amino acid supplementation reduces oxidative stress and prolongs survival in rats with advanced liver cirrhosis. PLoS One 8:e70309.
18. Khandekar MJ, Cohen P, Spiegelman BM (2011). Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11:886-895.
19. Kim SA, Marshall MA, Melman N, Kim HS, Müller CE, Linden J, Jacobson KA (2002). Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 45:2131-2138.
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
21. Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, et al. (2014). Nonalcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett 342:60-69.
22. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM (2004). Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 41:592-598.
23. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE (2008). The lysosomalmitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 47:1495-1503.
24. Massart J, Robin MA, Noury F, Fautrel A, Lettéron P, Bado A, et al. (2012). Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. Br J Pharmacol 165:1361-1374.
25. Menendez JA, Lupu R (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777.
26. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E (2012). Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302:G1310-G1321.
27. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. (2006). Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35:204-214.
28. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. (2010). Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208.
29. Peterson TC, Peterson MR, Raoul JM (2011). The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis. Eur J Pharmacol 662:47-54.
30. Postic C, Girard J (2008). The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 34(Pt 2):643-648.
31. Powell EE, Jonsson JR, Clouston AD (2005). Steatosis: co-factor in other liver diseases. Hepatology 42:5-13.
32. Quan HY, Kim do Y, Chung SH (2013). Caffeine attenuates lipid accumulation via activation of AMP-activated protein kinase signaling pathway in HepG2 cells. BMB Rep 46:207-212.
33. Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, et al. (1997). In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40:475-480.
34. Semmler J, Gebert U, Eisenhut T, Moeller J, Schönharting MM, Alléra A, Endres S (1993). Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78:520-525.
35. Shimizu M, Yasuda Y, Sakai H, Kubota M, Terakura D, Baba A, et al. (2011). Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 11:281.
36. Shimizu M, Shirakami Y, Hanai T, Imai K, Suetsugu A, Takai K, et al. (2014). Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Mol Nutr Food Res 58:124-135.
37. Shirakami Y, Gottesman ME, Blaner WS (2012). Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin: retinol acyltransferasedeficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis 33:268-274.
38. Siegel AB, Zhu AX (2009). Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115:5651-5661.
39. Starley BQ, Calcagno CJ, Harrison SA (2010). Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820-1832.
40. Terakura D, Shimizu M, Iwasa J, Baba A, Kochi T, Ohno T, et al. (2012). Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Carcinogenesis 33:2499-2506.
41. Tilg H, Moschen AR (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836-1846.
42. Videla LA, Rodrigo R, Araya J, Poniachik J (2004). Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 37:1499-1507.
43. Watanabe N, Takai K, Imai K, Shimizu M, Naiki T, Nagaki M, et al. (2011). Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. J Clin Biochem Nutr 49:153-158.
44. Windmeier C, Gressner AM (1997). Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 29:181-196.
45. Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, et al. (2005). Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 41:1316-1322.
46. Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, et al. (2010). Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 101:1701-1707.
47. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ (2011). Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54:1610-1619.
48. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, et al. (2012). Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 56:1291-1299.